Amgen's Imdelltra Combination Therapy Reduces Death Risk by 58% in Extensive-Stage Small Cell Lung Cancer
Late-stage clinical trial results show that combining Amgen's immunotherapy drug, Imdelltra, with AstraZeneca's Imfinzi significantly improves survival rates for patients with extensive-stage small cell lung cancer (ES-SCLC). The combination therapy extended median overall survival to 21.1 months, compared to just 12.7 months when using Imfinzi alone, representing a 58% reduction in the risk of death. The trial evaluated the regimen as maintenance therapy for patients whose disease had not progressed following initial chemotherapy and Imfinzi treatment. These results suggest a potential shift in the standard of care for this aggressive cancer, which affects approximately 31,000 people annually in the U.S. For Amgen, these findings bolster the commercial outlook for Imdelltra, which is trending toward blockbuster status. The drug reported $288 million in Q2 sales (up 115% year-over-year) and has already reached $627 million in global sales for 2025.
Topics: clinical trial results immunotherapy lung cancer treatment oncology